Federal Register / Vol. 88, No. 198 / Monday, October 16, 2023 / Notices 71371 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

Alzheimer’s Disease and its Related 

Dementias. 

Date: November 8–9, 2023. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mariam Zaka, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1009J, 

Bethesda, MD 20892, (301) 435–1042, 

zakam2@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Motor System, Pain, and Olfaction. 

Date: November 8, 2023. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kirk Thompson, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, 301–435– 

1242, kgt@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Myalgic 

Encephalomyelitis-Chronic Fatigue 

Syndrome. 

Date: November 8, 2023. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Roger Janz, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–8515, janzr2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 11, 2023. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2023–22770 Filed 10–13–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; AREA/ 

REAP: Musculoskeletal, Oral, and Skin 

Sciences. 

Date: November 7, 2023. 

Time: 9:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Richard Ingraham, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, (301) 496– 

8551, ingrahamrh@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Musculoskeletal, Rehabilitation 

and Skin Sciences. 

Date: November 7–8, 2023. 

Time: 1:30 p.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Richard Ingraham, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, (301) 496– 

8551, ingrahamrh@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Chemistry, Biochemistry and 

Biophysics. 

Date: November 8–9, 2023. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Dennis Pantazatos, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–2381, dennis.pantazatos@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Neurodevelopment and Plasticity. 

Date: November 9, 2023. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Vanessa S. Boyce, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 4185, 

MSC 7850, Bethesda, MD 20892, (301) 402– 

3726, boycevs@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Research 

Enhancement Awards: Molecular Genetics, 

Cellular & Cancer Biology. 

Date: November 13, 2023. 

Time: 1:00 p.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Brian Paul Chadwick, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–3586, chadwickbp@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Psychopathology. 

Date: November 13, 2023. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Stephanie Christine Nagle 

Emmens, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 594–6604, 

nagleemmenssc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Cell Biology, Developmental 

Biology, and Bioengineering. 

Date: November 14, 2023. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Alexander Gubin, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4196, 

MSC 7812, Bethesda, MD 20892, 301–435– 

2902, gubina@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Drug Discovery for Aging, 

Neurodegenerative and Neurological 

Disorders. 

Date: November 16–17, 2023. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Kathryn Partlow, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1016D, 


ddrumheller on DSK120RN23PROD with NOTICES1
71372 Federal Register / Vol. 88, No. 198 / Monday, October 16, 2023 / Notices 

Bethesda, MD 20892, (301) 594–2138, 

partlowkc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Drug Discovery Involving the 

Nervous System. 

Date: November 16–17, 2023. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lai Yee Leung, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1011D, 

Bethesda, MD 20892, (301) 827–8106, 

leungl2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 11, 2023. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2023–22769 Filed 10–13–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Request for Information; Potential 

Changes to its Evidence-Based 

Practices Resource Center; Notice of 

Correction 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice; correction. 

SUMMARY: The Substance Abuse and 

Mental Health Services Administration 

published a document in the Federal 

Register of September 7, 2023, 

announcing a Notice of request for 

information (RFI). The document 

contained incorrect date in the DATES

section. 

FOR FURTHER INFORMATION CONTACT: 

Carter A Roeber, Telephone number 

(240) 276–1488, Email: Carter.Roeber@

samhsa.hhs.gov, or EBPRC@

samhsa.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Correction 

In the Federal Register of September 

7, 2023, in FR Doc. 2023–19272, on 

pages 61608 and 61609, in the second 

column, correct the DATES caption to 

read: 

Comments or feedback on this notice 

must be received by end of business 

day, November 7, 2023. 

Dated: October 11, 2023. 

Carlos Castillo, 

Committee Management Officer. 

[FR Doc. 2023–22792 Filed 10–13–23; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Extension and Expansion of 

Declaration Zone Test 

AGENCY: U.S. Customs and Border 

Protection, DHS. 

ACTION: General notice. 

SUMMARY: On August 30, 2021, U.S. 

Customs and Border Protection (CBP) 

announced in the Federal Register that 

CBP would conduct a Declaration Zone 

test at cruise terminal facilities at 

participating sea ports of entry (POEs) 

that would run for approximately two 

years. This document announces that 

CBP is extending the test period for an 

additional two years. In addition to the 

extension, this document announces 

that CBP intends to expand the 

Declaration Zone test to up to eighteen 

additional sea POEs, as well as to 

travelers being processed in Simplified 

Arrival for open loop cruises. The 

Declaration Zone test allows for 

streamlined processing by allowing a 

demonstrative initial declaration for 

arriving travelers in lieu of an oral or 

written declaration of all articles 

brought into the United States to a CBP 

officer as required by current CBP 

regulations. 

DATES: CBP is extending the Declaration 

Zone test at cruise terminal facilities at 

participating sea POEs until October 16, 

2025. CBP is expanding the Declaration 

Zone test to eligible open loop cruises 

no sooner than October 1, 2023. The 

expansion date may vary at each 

location. 

ADDRESSES: Written comments 

concerning program, policy, and 

technical issues may be submitted at 

any time during the test period via 

email to BiometricSea@cbp.dhs.gov. 

Please use ‘‘Comment on Declaration 

Zone Test’’ in the subject line of the 

email. 

FOR FURTHER INFORMATION CONTACT: 

Maria Rivera, Program Manager, 

Biometric Entry-Exit Strategic 

Transformation, Office of Field 

Operations, maria.c.rivera@cbp.dhs.gov 

or (202) 325–4596. 

SUPPLEMENTARY INFORMATION: 

Background 

On August 30, 2021, U.S. Customs 

and Border Protection (CBP) announced 

in the Federal Register (86 FR 48436) 

that CBP would conduct a Declaration 

Zone test at cruise terminal facilities at 

participating sea ports of entry (POEs). 

The notice describes the Declaration 

Zone test, while setting forth 

requirements for participating in the 

test, the duration of the test, and how 

CBP will evaluate the test. The notice 

also invites public comment on any 

aspect of the test. In brief, the 

Declaration Zone test fulfills the 

declaration requirement under CBP 

regulations, while also allowing for 

streamlined processing. Current CBP 

regulations require each traveler to 

provide an oral or written declaration of 

all articles brought into the United 

States to a CBP officer. See 19 CFR part 

148, subpart B. The Declaration Zone 

test provides arriving travelers with an 

alternative method to meet this 

requirement by allowing a 

demonstrative initial declaration 

through the use of declaration zones at 

cruise terminal facilities at select sea 

POEs. 

Description and Procedures 

The 2021 notice provides the 

description and procedures for the 

Declaration Zone test. 86 FR 48437. 

Within a cruise terminal facility 

participating in the Declaration Zone 

test, two distinct customs declaration 

zone queues are established for entering 

the egress area: one for No Items to 

Declare and another for Items to 

Declare. Signage is posted to clearly 

label the queues at the entrance to the 

egress area after travelers collect their 

luggage. The physical act of selecting 

the No Items to Declare queue or the 

Items to Declare queue in and of itself 

constitutes an initial demonstrative 

declaration. CBP officers conduct roving 

enforcement operations within the 

baggage collection and egress area to 

ensure traveler compliance. 

No Items To Declare Queue 

Travelers who determine they have 

nothing to declare enter the No Items to 

Declare queue and proceed through the 

egress area to the facility exit. CBP 

officers conduct roving operations in the 

No Items to Declare zone to affirm 

traveler compliance, receive oral 

declarations, and make referrals to 

secondary inspection as necessary. 

Travelers who are not questioned by 

CBP officers conducting roving 

operations may proceed to the exit. 


ddrumheller on DSK120RN23PROD with NOTICES1